 |
Indication & Dosage |
| |
| |
| Parenteral |
| INDUCTION AND MAINTENANCE OF REMISSION IN ACUTE LEUKAEMIA |
| Child:
100 mg/m2 BSA bid by rapid inj or 100 mg/m2 BSA daily by continuous infusion given for 5-10 days. |
| |
| Parenteral |
| INDUCTION AND MAINTENANCE OF REMISSION IN ACUTE LEUKAEMIA |
| Adult:
100 mg/m2 BSA bid by rapid inj or 100 mg/m2 BSA daily by continuous infusion given for 5-10 days. Maintenance: 1-1.5 mg/kg 1-2 times wkly via IV or SC admin. For refractory disease: High dose regimen is used: up to 3 g/m2 BSA every 12 hr for up to 6 days, given as an IV infusion over at least 1 hr. |
| |
| Intrathecal |
| LEUKAEMIC MENINGITIS |
| Adult:
10-30 mg/m2 BSA every 2-4 days. For lymphomatous meningitis: 50 mg every 2 wk for 5 doses, then every 4 wk for 5 doses |
|
| |
|
| Administration |
Hepatic and renal dysfunction, severe infections, preexisting drug-induced bone marrow suppression. Monitor WBC, platelet counts and blood uric acid frequently. Assess renal and hepatic function periodically. |
| |
|
| Precautions |
Hepatic and renal dysfunction, severe infections, preexisting drug-induced bone marrow suppression. Monitor WBC, platelet counts and blood uric acid frequently. Assess renal and hepatic function periodically. |
| |
|
Potentially Life-threatening
Adverse Drug Reactions |
Dementia, GI disturbances, hepatic and renal dysfunction, neurotoxicity, rashes, oral and anal ulceration, GI haemorrhage, oesophagitis, conjunctivitis, flu-like syndrome, anaphylactoid reactions.May reduce efficacy of gentamicin, digoxin and flucytosine. |
| |
|
| Adverse Drug Reactions |
Convulsions. Cerebellar dysfunction, respiratory distress syndrome, GI perforation, bone marrow suppression. |
| |
|
| Interactions |
May reduce efficacy of gentamicin, digoxin and flucytosine. |
| |
|
|
|
